Merck, Sharp & Dohme's Capvaxive Approved by European Commission for Pneumococcal Prevention
CompanyDrug

Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials

Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933
CompanyDeals

Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933

Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
CompanyDeals

Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization

Shanghai Junshi Biosciences' Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma
CompanyDrug

Shanghai Junshi Biosciences’ Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma

Zhejiang Funuo Medicine Launches Triple Cream for Melasma Treatment in China
CompanyDrug

Zhejiang Funow Medicine Launches Triple Cream for Melasma Treatment in China

Luye Pharma's BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer
CompanyDrug

Luye Pharma’s BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer

Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI
CompanyDeals

Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI

Bayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372
CompanyDeals

Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372

Shanghai Liferiver Bio-Tech's HCV Nucleic Acid Test Kit Receives NMPA Approval
CompanyDrug

AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment

Shanghai Liferiver Bio-Tech's HCV Nucleic Acid Test Kit Receives NMPA Approval
CompanyMedical Device

Shanghai ZJ Bio-Tech’s HCV Nucleic Acid Test Kit Receives NMPA Approval

Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
CompanyDeals

Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources